Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
29.61
-0.44 (-1.46%)
May 14, 2025, 10:14 AM - Market open

Vaxcyte Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Cost of Revenue
--7523--
Upgrade
Gross Profit
---75-23--
Upgrade
Selling, General & Admin
105.6892.960.739.8125.2616.02
Upgrade
Research & Development
530.19476.64332.34169.4578.4173.56
Upgrade
Operating Expenses
635.87569.55393.04209.26103.6789.58
Upgrade
Operating Income
-635.87-569.55-468.04-232.26-103.67-89.58
Upgrade
Interest Expense
----0-0.01-0.01
Upgrade
Interest & Investment Income
121.26109.9962.918.360.340.24
Upgrade
Currency Exchange Gain (Loss)
----1.67-2.35
Upgrade
Other Non Operating Income (Expenses)
4.98-4.382.870.421.592.48
Upgrade
EBT Excluding Unusual Items
-509.63-463.93-402.27-223.49-100.08-89.22
Upgrade
Gain (Loss) on Sale of Investments
----0-
Upgrade
Pretax Income
-509.63-463.93-402.27-223.49-100.08-89.22
Upgrade
Net Income
-509.63-463.93-402.27-223.49-100.08-89.22
Upgrade
Net Income to Common
-509.63-463.93-402.27-223.49-100.08-89.22
Upgrade
Shares Outstanding (Basic)
12812297655230
Upgrade
Shares Outstanding (Diluted)
12812297655230
Upgrade
Shares Change (YoY)
23.64%25.57%49.75%24.95%75.73%678.53%
Upgrade
EPS (Basic)
-3.98-3.80-4.14-3.44-1.93-3.02
Upgrade
EPS (Diluted)
-3.98-3.80-4.14-3.44-1.93-3.02
Upgrade
Free Cash Flow
-593.62-571.79-364.67-176.44-127.95-47.78
Upgrade
Free Cash Flow Per Share
-4.64-4.69-3.75-2.72-2.46-1.62
Upgrade
EBITDA
-626.91-562.54-464.89-229.42-101.87-88.18
Upgrade
D&A For EBITDA
8.9673.162.831.81.41
Upgrade
EBIT
-635.87-569.55-468.04-232.26-103.67-89.58
Upgrade
Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q